

BEST AVAILABLE COPY

INTERNATIONAL COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 21 March 2000 (21.03.00)	
International application No. PCT/AU99/00567	Applicant's or agent's file reference 22530
International filing date (day/month/year) 14 July 1999 (14.07.99)	Priority date (day/month/year) 14 July 1998 (14.07.98)
Applicant MCCLUSKEY, Adam et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
11 February 2000 (11.02.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Olivia RANAIVOJAONA Telephone No.: (41-22) 338.83.38
---	---

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 99/00567

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ :C07D 493/18, 493/08, 491/18, 495/18, 487/18, A61K 31/34, 31/38, 31/41																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols)																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN substructure + Keywords- cantharidin?, modif?, deriv?, analog?, phosphatase? Molecular Formula C ₁₀ H ₁₂ O ₅ /mF, C ₁₄ H ₁₂ O ₅ /mF																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	The Merck Index, Tenth Edition 1983. Page 241 See entry 1728 Cantharidin	4																				
X	AFMC International Medical Chemistry. Pages 125-130, 1997. Quinn, Ronald J. "Marine Pharmaceuticals: receptor/ligand interactions and cell signalling." See pages 125 and 127, Abstract and formulas 5 and 6 in particular.	1,2,3,4,26																				
X	The Journal Of Pharmacology & Experimental Therapeutics. Vol. 280, pp 1152-1158, 1997. Laidley et. al. "Protein Phosphatase in Neuroblastoma Cells:[³ H]Cantharidin Binding Site in Relation to Cytotoxicity. See in particular Abstract and structure at figure 1 (page 1153)	1,2,3,4																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 8 September 1999		Date of mailing of the international search report 21 SEP 1999																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer K. LEVER Telephone No.: (02) 6283 2254																				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00567

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4220594 Sprague Published 2 September 1980. See formula VII column 2, Line 67 column 1 to line 68 column 4, and also the examples.	4,7-12,26
X	Hetreocycles, Vol 24, No.7 1986. Matsumoto et al. Pages 1835-1839, "The High Pressure Mediated Reaction of π -Excessive Heterocycles with Maleic Anhydride Derivatives: A Synthetic Approach to Cantharidin Analogues". See whole document.	7-12
X	Journal of Pharmaceutical Sciences: a publication of the American Pharmaceutical Association. Vol 78 (1) pages 66-7. Walter WG "Antitumor Imide Derivatives of 7-Oxabicyclo - [2.2.1]heptane-2,3-dimethyl-2,3-dicarboxylic Acid. See page 66 formulaes 2 and 5a, 5b.	4,13,14,16,27, 28,29
X	Anticancer Research, Vol. 17, pp 2095-2098, 1997. Tsauer et al. "The Effects of Cantharidin Analogues on Xanthine Oxidase". In particular page 2096 see formula 4.	4,26
X	Abstracts of Japanese Patents No 63-170383 published 14 July 1988. NIPPON ZEON CO LTD	4
X	US 5399725 Poss et al. Published 21 March 1995. See formula IX in column 7.	4,5,6
X	US 4228180 Sprague Published 14 October 1980. See column 1 line 58 to column 2 line 24. Also structures III and IV.	4,7-12, 26
X	WO 95/17901 Matrix Pharmaceutical, Inc. Published 6 July 1995. See page 6 line 24, page 12 lines 12-20 and example 7 in particular Table 10.	4,13,14,15,27, 28
X	US 3954913 Uebele et al. Published 4 May 1976. See column 1 structure II when Z= CH ₃	4,26

INTERNATIONAL SEARCH REPORT

International application No. *

PCT/AU 99/00567

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-25, 27-29 in part
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The search was based on the exemplified structures. Thus not all possible compounds falling within the broad scope of the above claims have been fully searched. The documents cited in this report represent only a selection from the vast number of relevant documents.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU 99/00567

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	4220594	DE	2847832	GB	2008107	FR	2407921
US	4228180	DE	3041114	GB	2062629	FR	2468607
WO	95/17901	AU	14386/95	EP	739210	US	5573781
US	3954913	AU	87457/75	FR	2296665	GB	1495168
US	5399725	AU	63295/94	EP	626384	CA	2124242
END OF ANNEX							

PATENT COOPERATION TREATY PCT

REC'D 10 NOV 2000
WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

15

Applicant's or agent's file reference 22530	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International application No. PCT/AU99/00567	International filing date (<i>day/month/year</i>) 14 July 1999	Priority Date (<i>day/month/year</i>) 14 July 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ C07D 493/18, 493/08, 491/18, 495/18, 487/18, A61K 31/34, 31/38, 31/41 A61P 35/00, 35/02, 35/04		
Applicant THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	This REPORT consists of a total of 5 sheets, including this cover sheet. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheet(s).																								
3. This report contains indications relating to the following items: <table style="width: 100%; margin-top: 10px;"> <tr> <td style="width: 5%;">I</td> <td style="width: 5%; text-align: center;"><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>		I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input checked="" type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input checked="" type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input checked="" type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input checked="" type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 11 February 2000	Date of completion of the report 18 October 2000
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer K. LEVER Telephone No. (02) 6283 2254

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
 pages , filed with the demand,
 pages received on with the letter of
- ☐ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages received on with the letter of
- ☐ the drawings, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be nonobvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos: 1-25, 27-29 in part.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claim Nos. 1-25, 27-29 in part. The search was based on the exemplified structures. Thus not all possible compounds falling within the broad scope of these claims have been fully searched.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 5,6,12,14,17-25 in part	YES
	Claims 1-4,7-11,13,15,16,26-29	NO
Inventive step (IS)	Claims 5,6,14,17-25 in part	YES
	Claims 1-4,7-13,15,16,26-29	NO
Industrial applicability (IA)	Claims 1-29	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)**Citations:**

- D1. The Merck Index, Tenth Edition 1983. Page 241. Entry 1728.
D2. AFMC International Medical Chemistry. Pages 125-130, 1997.
D3. The Journal of Pharmacy & Experimental Therapeutics. Vol.280, pp 1152-1158, 1997.
D4. US 4220594.
D5. Heterocycles, Vol 24, No.7 1986. Pages 1835-1839.
D6. Journal of Pharmaceutical Sciences: Vol 78(1) pages 66-7.
D7. Anticancer Research, Vol. 17, pages 2095-2098, 1997.
D8. Abstracts of Japanese Patents No 63-170383 published 14 July 1988.
D9. US 5399725.
D10. US 4228180.
D11. WO 95/17901.
D12. US 3954913.

Explanations:

D1 discloses naturally occurring cantharidin. D2-D4, D7-D12 all disclose at least one of the compounds defined in claims 4 and 26.

D2 and D3 demonstrate the inhibitory activity of cantharidin analogues against protein phosphatase 2A.

D5 and D10 each disclose a method of producing an anhydride modified Cantharidin analogue by reacting Maleic Anhydride with furan. The product then undergoes hydrogenation and ring opening.

D6 This document discloses the compounds of claim 4 as having anti tumour inhibitory activity.

Therefore Claims 1-4,7-11,13,15,16,26-29 are considered not novel.

D4 and D5 both disclose the methods of claims 7-11 using furan. Claim 12 defines the same method using thiophene. This structural difference is minimal and cannot be considered as involving an inventive step, since the person skilled in the art, faced with the problem of finding anhydride modified cantharidin analogues, would regard it as a logical alternative.

Therefore Claims 1-4,7-13,15,16,26-29 are not considered to possess an inventive step.

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 4 is not clear because options for Y, CH₂ OH and CH₂ OR are not possible as the valences are incorrect.



Claim 5 is not clear because it is not clear what can be included in the phrase 'carbon spacer between 6 and 10 carbon atoms'. The claim appears to be incorrectly appended to claim 3 instead of claim 4.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 493/18, 493/08, 491/18, 495/18, 487/18, A61K 31/34, 31/38, 31/41		A1	(11) International Publication Number: WO 00/04023
			(43) International Publication Date: 27 January 2000 (27.01.00)
(21) International Application Number: PCT/AU99/00567		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
(22) International Filing Date: 14 July 1999 (14.07.99)			
(30) Priority Data: PP 4665 14 July 1998 (14.07.98) AU			
(71) Applicant (for all designated States except US): THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED [AU/AU]; Industry Development Center, University Drive, Callaghan, NSW 2308 (AU).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MCCLUSKEY, Adam [GB/AU]; 19 Simpson Court, Mayfield, NSW 2304 (AU). SAKOFF, Jennette, A. [AU/AU]; 61 Gilsmere Street, Jewells, NSW 2280 (AU). ACKLAND, Stephen [AU/AU]; 95 Carrington Parade, New Lambton Heights, NSW 2305 (AU). SIM, Alistair, T., R. [AU/AU]; The University of Newcastle, The Faculty of Medical and Health Sciences, Dept. of Medical Biochemistry, University Drive, Callaghan, NSW 2308 (AU).			
(74) Agent: BALDWIN SHELSTON WATERS; 60 Margaret Street, Sydney, NSW 2000 (AU).			

(54) Title: ANHYDRIDE MODIFIED CANTHARIDIN ANALOGUES USEFUL IN THE TREATMENT OF CANCER



(57) Abstract

Anhydride modified cantharidin analogues useful in the treatment of certain forms of cancer also methods for the screening for anti-cancer activity of these analogues and/or their ability to sensitise cancer cells to cancer treatment. The modified cantharidin analogues have structure (I) or (II), wherein R₁, R₂, R₃ and R₄ are H, aryl or alkyl; X is O, N or S; Y is O, S, NH, NR; R is alkyl or aryl; A and B are H or CH₃; W and Z are CHOH or C=O. These compounds inhibit protein phosphatase.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00567

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶:C07D 493/18, 493/08, 491/18, 495/18, 487/18, A61K 31/34, 31/38, 31/41

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 STN substructure + Keywords- cantharidin?, modif?, deriv?, analog?, phosphatase?
 Molecular Formula C₁₀H₁₂O₅/mF, C₁₄H₁₂O₅/mF

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Merck Index, Tenth Edition 1983: Page 241 See entry 1728 Cantharidin	4
X	AFMC International Medical Chemistry. Pages 125-130, 1997. Quinn, Ronald J. "Marine Pharmaceuticals: receptor/ligand interactions and cell signalling." See pages 125 and 127, Abstract and formulas 5 and 6 in particular.	1,2,3,4,26
X	The Journal Of Pharmacology & Experimental Therapeutics. Vol. 280, pp 1152-1158, 1997. Laidley et. al. "Protein Phosphatase in Neuroblastoma Cells: [³ H]Cantharidin Binding Site in Relation to Cytotoxicity. See in particular Abstract and structure at figure 1 (page 1153)	1,2,3,4

☒ Further documents are listed in the continuation of Box C

☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
8 September 1999

Date of mailing of the international search report
21 SEP 1999

Name and mailing address of the ISA/AU
 AUSTRALIAN PATENT OFFICE
 PO BOX 200
 WODEN ACT 2606
 AUSTRALIA
 Facsimile No.: (02) 6285 3929

Authorized officer

K. LEVER
 Telephone No.: (02) 6283 2254

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00567

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4220594 Sprague Published 2 September 1980. See formula VII column 2, Line 67 column 1 to line 68 column 4, and also the examples.	4,7-12,26
X	Hetreocycles, Vol 24, No.7 1986. Matsumoto et al. Pages 1835-1839, "The High Pressure Mediated Reaction of π -Excessive Heterocycles with Maleic Anhydride Derivatives: A Synthetic Approach to Cantharidin Analogues". See whole document.	7-12
X	Journal of Pharmaceutical Sciences: a publication of the American Pharmaceutical Association. Vol 78 (1) pages 66-7. Walter WG. "Antitumor Imide Derivatives of 7-Oxabicyclo - [2.2.1]heptane-2,3-dimethyl-2,3-dicarboxylic Acid. See page 66 formulaes 2 and 5a, 5b.	4,13,14,16,27, 28,29
X	Anticancer Research, Vol. 17, pp 2095-2098, 1997. Tsauer et al. "The Effects of Cantharidin Analogues on Xanthine Oxidase". In particular page 2096 see formula 4.	4,26
X	Abstracts of Japanese Patents No 63-170383 published 14 July 1988. NIPPON ZEON CO LTD	4
X	US 5399725 Poss et al. Published 21 March 1995. See formula IX in column 7.	4,5,6
X	US 4228180 Sprague Published 14 October 1980. See column 1 line 58 to column 2 line 24. Also structures III and IV.	4,7-12, 26
X	WO 95/17901 Matrix Pharmaceutical, Inc. Published 6 July 1995. See page 6 line 24, page 12 lines 12-20 and example 7 in particular Table 10.	4,13,14,15,27, 28
X	US 3954913 Uebele et al. Published 4 May 1976. See column 1 structure II when Z= CH ₃	4,26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00567

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-25, 27-29 in part
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The search was based on the exemplified structures. Thus not all possible compounds falling within the broad scope of the above claims have been fully searched. The documents cited in this report represent only a selection from the vast number of relevant documents.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members



International application No.
PCT/AU 99/00567

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	4220594	DE	2847832	GB	2008107	FR	2407921
US	4228180	DE	3041114	GB	2062629	FR	2468607
WO	95/17901	AU	14386/95	EP	739210	US	5573781
US	3954913	AU	87457/75	FR	2296665	GB	1495168
US	5399725	AU	63295/94	EP	626384	CA	2124242
END OF ANNEX							



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 493/18, 493/08, 491/18, 495/18, 487/18, A61K 31/34, 31/38, 31/41	A1	(11) International Publication Number: WO 00/04023 (43) International Publication Date: 27 January 2000 (27.01.00)
(21) International Application Number: PCT/AU99/00567 (22) International Filing Date: 14 July 1999 (14.07.99) (30) Priority Data: PP 4665 14 July 1998 (14.07.98) AU (71) Applicant (for all designated States except US): THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED [AU/AU]; Industry Development Center, University Drive, Callaghan, NSW 2308 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): MCCLUSKEY, Adam [GB/AU]; 19 Simpson Court, Mayfield, NSW 2304 (AU). SAKOFF, Jennette, A. [AU/AU]; 61 Gilsmere Street, Jewells, NSW 2280 (AU). ACKLAND, Stephen [AU/AU]; 95 Carrington Parade, New Lambton Heights, NSW 2305 (AU). SIM, Alistair, T., R. [AU/AU]; The University of Newcastle, The Faculty of Medical and Health Sciences, Dept. of Medical Biochemistry, University Drive, Callaghan, NSW 2308 (AU). (74) Agent: BALDWIN SHELSTON WATERS; 60 Margaret Street, Sydney, NSW 2000 (AU).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ANHYDRIDE MODIFIED CANTHARIDIN ANALOGUES USEFUL IN THE TREATMENT OF CANCER		
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div> </div>		
(57) Abstract <p>Anhydride modified cantharidin analogues useful in the treatment of certain forms of cancer also methods for the screening for anti-cancer activity of these analogues and/or their ability to sensitise cancer cells to cancer treatment. The modified cantharidin analogues have structure (I) or (II), wherein R₁, R₂, R₃ and R₄ are H, aryl or alkyl; X is O, N or S; Y is O, S, NH, NR; R is alkyl or aryl; A and B are H or CH₃; W and Z are CHOH or C=O. These compounds inhibit protein phosphatase.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANHYDRIDE MODIFIED CANTHARIDIN ANALOGUES USEFUL IN THE TREATMENT OF CANCER

TECHNICAL FIELD

This invention relates to compounds useful in the treatment of certain forms of cancer; processes for producing these compounds; methods of treatment using these compounds *per se*; methods of treatment using these compounds which methods also increase the sensitivity of cancer cells to other treatments; methods of screening these compounds for anti-cancer activity; and methods of screening these compounds for anti-cancer activity and/or ability to sensitise cancer cells to other methods of treatment. More particularly, the compounds are specific inhibitors of protein phosphatases 1 and 2A.

BACKGROUND ART

Protein phosphatase inhibitors and the abrogation of cell cycle checkpoints

The regulation of protein phosphatases is integral to the control of many cell processes, including cell growth, transformation, tumour suppression, gene transcription, apoptosis, cellular signal transduction, as neurotransmission, muscle contraction, glycogen synthesis, and T-cell activation. The role of protein phosphatases in many of these processes is often mediated via alterations in the cell cycle. Cell cycle progression is tightly regulated to ensure the integrity of the genome. During cell division it is imperative that each stage of the cell cycle be completed before entry into the next, and this is achieved through a series of checkpoints. The cell cycle can be broken down into four phases, the first gap (G_1), is followed by a phase of DNA synthesis (S-phase); this is followed by a second gap (G_2) which in turn is followed by mitosis (M) which produces two daughter cells in G_1 . There are two major control points in the cell cycle, one late in G_1 , and the other at the G_2 /M boundary. Passage through these control points is

controlled by a universal protein kinase, cdk1. The kinase activity of cdk1 is dependant on phosphorylation and the association with a regulatory subunit, cyclin B. The periodic association of different cyclins with different cyclin dependent kinases (cdk) has been shown to drive different phases of the cell cycle; thus cdk4-cyclin D1 drives cells through mid G₁, cdk2-cyclin E drives cells in late G₁, cdk2-cyclin A controls entry into S-phase and cdc2-cyclin B drives the G₂/M transition (O'Connor, 1996, 1997).

Following DNA damage induced by chemotherapy or radiation treatment these checkpoints are responsible for halting cell cycle progression in G₁, S and/or G₂ phases (O'Connor, 1996). The cell undergoes a cell cycle arrest so that the damaged DNA can be repaired before entry into S phase or mitosis. The phase at which the cell cycle is halted will depend upon the type of DNA damaging agent used and the point during the cell cycle that the damage was incurred (O'Connor, 1997). The cell cycle is controlled and regulated by an intricate phosphorylation network (Stein et al., 1998). More particularly, activation of cdk/cyclin complexes requires the phosphorylation of a conserved threonine residue, which are catalysed by CAK kinase, as well as the removal of inhibitory phosphorylations by the phosphatase cdc25. Cdc25 is only active in its phosphorylated form. Therefore, protein phosphatase 2A (PP2A) can inhibit the activation of cdk/cyclin complexes by inhibiting CAK activity and by dephosphorylating cdc25. The G₁/S checkpoint is predominantly regulated by the cdk/cyclin D/E complex that mediates its effects by phosphorylating and inactivating the tumour suppressor protein retinoblastoma (pRb). The phosphorylation of pRb prevents it from interacting with the S-phase transcription factor E2F. E2F controls the transcription of proteins needed for DNA synthesis and entry into S-phase including thymidylate synthase.

Accordingly, the inactivation of pRb by phosphorylation permits entry into the S-phase and vice versa. However, protein phosphatase 1 (PP1) can dephosphorylate pRb and inhibit the cell cycle (Durfee et al., 1993). Thus, PP1 and PP2A are both negative regulators of the cell cycle. Inhibition of PP1 and PP2A would abrogate these checkpoints and prematurely force cells through the cell cycle.

Serine/threonine phosphatases, which are responsible for protein dephosphorylation, comprise a unique class of enzymes consisting of four primary subclasses based on their differences in substrate specificity and environmental requirements. Of the serine/threonine phosphatases, protein phosphatases 1 and 2A (PP1 and PP2A, respectively) share sequence identity between both enzyme subunits (50% for residues 23-292; 43% overall), are present in all eukaryotic cells and are together responsible for 90% of all cellular dephosphorylation. Knowledge of structure and subsequent correlation of binding function for both PP1 and PP2A would therefore provide a vital link toward understanding the biochemical role of these enzymes. A goal of the medicinal chemist is the development of potent and selective inhibitors of these protein phosphatases.

The natural toxins, okadaic acid, calyculin A, microcystin-LR and tautomycin are representative of a structurally diverse group of compounds that are all potent protein phosphatase 1 (PP1) and 2A (PP2A) inhibitors. Okadaic acid is more specific for PP2A (IC_{50} 1 nM) than PP1 (IC_{50} 60 nM), while calyculin is slightly more specific for PP1 (IC_{50} 0.5-1.0 nM) than PP2A (IC_{50} 2 nM). All of these phosphatase inhibitors are known to abrogate cell cycle checkpoints, particularly the G_2 checkpoint of the cell cycle and induce cellular mitoses (Yamashita et al., 1990). Abrogation of the G_2 checkpoint means that the cell does not have the capacity to detect DNA damage or malformation of the

genome prior to entry into mitosis. Therefore, cells which have a deficient G₂ checkpoint are unstable, and incapable of detecting DNA damage, initiating G₂ arrest, or undergoing DNA repair. Such cells enter the mitotic stage of the cell cycle prematurely with malformed spindles. The abrogation is of the G₂ checkpoint in the cell cycle by okadaic acid is mediated via the activation of cdc2/H1 kinase, the major mitotic inducer, and results in a premature mitotic state (Yamashita et al., 1990). Although okadaic acid is known as a tumour promoter, in some cell types, it has been shown to revert the phenotype of oncogene-transformed cells to that of normal cells, and to inhibit neoplastic transformation of fibroblasts (Schonthal, 1991).

Furthermore, okadaic acid has been shown to selectively enhance the cytotoxicity of vinblastine and the formation of apoptotic cells, in HL60 cells which are p53 null (Kawamura, 1996). Interestingly, calyculin enhances irradiation killing in fibroblast cells at doses that are non toxic when given as a single treatment. (Nakamura and Antoku, 1994). Data also shows that okadaic acid can abrogate the G₁/S checkpoint of the cell cycle. In this context, okadaic acid has been shown to override the S-phase checkpoint and accelerate progression of G₂-phase to induce premature mitosis (Gosh et al., 1996). In addition, okadaic acid has been shown to significantly increase the fraction of quiescent cells entering the S-phase via modifications in the phosphorylation state of pRb (Lazzereschi et al., 1997). Other studies have shown that the hyperphosphorylation state of pRb forces cells prematurely into S-phase and pRb can be kept in a phosphorylated state via protein phosphate inhibition (Herwig and Strauss, 1997). Cells lacking functional pRb show increased apoptosis and cytotoxicity following 5-fluorouracil and methotrexate treatment (Herwig and

Strauss, 1997). We propose that cell death would be substantially enhanced in cells forced to enter the S-phase prematurely (via G₁ checkpoint abrogation) and which were lacking key S-phase components such as dTMP (via TS inhibition).

The okadaic acids class of compounds, with the exceptions of okadaic acid, 5 cantharidin (Honaken) and thyriferyl 23-acetate (Matszawa et. al) (being PP2A selective) exhibit poor selectivity. Furthermore, the concentration of PP1 and PP2A inside cells is such that high concentrations of these inhibitors are required to generate a response *in vivo* resulting in the loss of effectiveness of any *in vitro* selectivity (Wang).

Cantharidin (exo.exo-2,3-dimethyl-7-oxobicyclo[2.2.1]heptane-2,3-dicarboxylic 10 acid anhydride), is a major component of the Chinese blister beetles:

Mylabris phalerata or *M. cichorii* (Yang; Cavill et. al). The dried body of these beetles has been used by the Chinese as a natural remedy for the past 2000 years. Although Western medicine decreed cantharidin to be too toxic in the early 1900's (Goldfarb et. al) its purported aphrodisiac qualities (the active ingredient of "Spanish Fly"), and its 15 widespread occurrence in cattle feed still results in numerous human and livestock poisonings (Schmitz).

Li and Casida, and previous work in this laboratory (McCluskey et. al) (and more recently Pombo-Villar, Sodeoka) has assisted in the delineation of certain features crucial for inhibition of PP2A by cantharidin analogues (Figure 1). However the 20 corresponding picture for PP1 is not so clear, the majority of data refers to possible interactions with the known crystal structures, and in some cases the inhibition values for PP1 are not reported.

Involvement of Tumour Suppressor Gene p53

The most commonly mutated gene in human cancers is the tumour suppressor gene p53, which is abnormally expressed in more than 50% of tumours. The development of chemotherapeutic agents which selectively target cancer cells with mutant p53 is certainly desirable, for two main reasons. Firstly, cells that have an abnormal p53 status are inherently resistant to conventional chemotherapy and produce the more common, and more aggressive tumours such as colon carcinoma and non small cell lung cancer. Secondly, a chemotherapy regime that targeted only those cells with a mutant p53 phenotype would potentially produce fewer side effects since only the cancer cells would be killed and not the p53 proficient normal healthy cells.

DISCLOSURE OF THE INVENTION


In relation to the discussion above, the present inventors believed that the replacement of the ether O atom of the anhydride with N or S (as N-H and N-R, where R = alkyl or aryl) would allow them to probe the H-bonding requirements of this region of cantharidin analogues. Previous studies in their laboratory had shown limited tolerance for modification of the 7-oxa position. An ability to modify these heteroatoms is crucial to the development of selective inhibitors based on this simple skeleton.

There is not, at present, an inhibitor with either absolute specificity or high enough selectivity which renders the inhibitor effectively specific in vivo.


It has surprisingly been found that anhydride modified cantharidin analogues, which are the subject of this invention, may possess one or more of the properties of being potent, selective, oxidatively stable, and cell permeable inhibitors of protein phosphatases 1 and 2A.

Therefore, according to the first aspect of this invention there are provided cell permeable inhibitors of protein phosphatases 1 and 2A, said inhibitors being anhydride modified cantharidin analogues.

According to a particular embodiment of the first aspect of this invention there are provided compounds of the formula:



wherein R_1 and R_2 are H, aryl or alkyl; X is O, N or S; Y is O, S, SR, NH, NR, CH_2OH , CH_2OR ; R is alkyl or aryl; A and B are H or CH_3 ; W and Z are $CHOH$ or $C=O$ and R_1 and R_2 can cyclise to form a ring as follows:



wherein R_3 and R_4 are H, aryl or alkyl.

The aryl group may suitably be phenyl or naphthyl for example, and may be attached via a carbon spacer of between 6 and 10 carbon atoms. The alkyl group may suitably be C_1 - C_{10} .

According to the second aspect of this invention there is provided a process for producing anhydride modified cantharidin analogues. The process may include the steps of:

dissolving a diene in a suitable solvent and adding to the resultant solution an ene.

According to a third aspect of the invention there is provided a process for producing anhydride modified cantharidin analogues, involving the step of reacting a
5 diene with an ene.

The process may further involve hydrogenation of the adduct of the diene and ene and/or optionally, ring opening of the adduct.

Generally, the reaction conditions for the production of the anhydride modified cantharidin analogues are dependent on the aromaticity of the starting diene. Suitable
10 reaction conditions are exemplified below.

According to a fourth aspect of this invention there is provided a method of treating a cancer which method comprises administering to a patient in need of such treatment, an effective amount of an anhydride modified cantharidin analogue of the first aspect of this invention, together with a pharmaceutically acceptable carrier, diluent
15 and/or excipient.

The method may be carried out in conjunction with one or more further treatments for treating the cancer.

According to a fifth aspect of this invention there is provided a method of sensitising cancer cells to at least one method of treating cancer, which method of sensitising comprises administering to a patient in need of such treatment, an effective
20 amount of an anhydride modified cantharidin analogue of the first aspect of this invention, together with a pharmaceutically acceptable carrier, diluent and/or excipient.

According to a sixth aspect of the invention there is provided a method of treating cancer which method comprises:

administering to a patient in need of such treatment, an effective amount of an anhydride modified cantharidin analogue to sensitise cancer cells of the patient to one or more cancer treatments; and utilising the one or more cancer treatments.

According to a seventh aspect of this invention there is provided a method of
5 screening a compound for anti-cancer activity.

According to an eighth aspect of this invention there is provided a method of screening compounds for use in the fourth aspect of this invention, said method comprising screening for anti-cancer activity; and screening for ability to abrogate either the G₁ or the G₂ checkpoint of the cancer cell cycle. The method may also comprise
10 screening for the ability of said compounds to sensitise cancer cells to one or more cancer treatments.

The one or more cancer treatments mentioned above may be selected from treatments involving cisplatin, irradiation, taxanes and antimetabolites.

The invention will hereinafter be described with reference to Examples and the
15 accompanying figures.

Brief Description of the Figures

Figure 1 is a schematic representation of the structure activity data generated for inhibition by PP2A by cantharidin analogues;

Figure 2: New cantharidin analogues.

20 Figure 3: Cytotoxicity of cantharidin and the new cantharidin analogues.

Figure 4: Cell cycle analysis 12h following exposure to cantharidin, MK-2 or MK-4.

Figure 5: Cell cycle analysis 18h after 6Gy of radiation and 12h after exposure to cantharidin, MK-2 or MK-4.

25 Figure 6 (a-c): Combination index versus fraction affected: HCT116 colon cells in simultaneous combination with cisplatin and MK-4.

Figure 7 (a-b): Combination index versus fraction affected: HT29 colon cells in simultaneous combination with cisplatin and MK-4.

Figure 8 (a-c): Combination index versus fraction affected: HCT116 colon cells in simultaneous combination with taxotere and MK-4

5 Figure 9 (a-c): Combination index versus fraction affected: HT29 colon cells in simultaneous combination with taxotere and MK-4.

Best and other Modes for Carrying Out the Invention

As mentioned above, the reaction conditions for producing anhydride modified cantharidin analogues encompassed by the present invention generally depend on the
10 aromaticity of the starting diene. This is illustrated by a description of examples of the methods wherein the starting materials are furan (Method 1 below); thiophene (Method 2 below); and pyrrole (Method 3 below).

Method 1: Furan as the starting diene

A solution of furan (5 equivalents) is dissolved in a suitable solvent (about 5
15 times the volume of furan, the solvent can be for example, ether (for room temperature reactions); or benzene or xylene (the latter two for reactions at 80 and 130°C respectively). To this solution is added one equivalent of the ene. The reaction is then heated (or stirred at room temperature), typically for 24 hours (2 days in the case of the room temperature reaction). Upon cooling (or standing at room temperature) a
20 precipitate forms and is collected by vacuum filtration. The adduct is then purified by recrystallisation from for example, chloroform or ethanol. In the case of the furan + maleic anhydride compound care is exercised to minimise heating as this causes a retro-Diels-Alder reaction yielding only the starting materials.

Method 2: Thiophene as the starting diene

Thiophene (1.016g, 0.012 mol) and maleic anhydride (0.558.0.006 mol) are mixed at room temperature in 2.5 mL of distilled dichloromethane. This mixture is then placed inside a high pressure reactor. They are compressed to a pressure of 17kbar at
5 40°C for a period of 71 hours, after which the pressure is released and the product purified by chromatography.

Method 3: Pyrrole as the starting diene

To $[\text{Os}(\text{NH}_3)_5\text{OsO}_2\text{CF}_3]$ (CF_3SO_3)₂, (0.3511 g, 0.4 mmol) and activated magnesium (0.1511 g), pyrrole (0.45 mL, 0.6 mmol), DME (1 mL) and DMAc (0.3 mL)
10 are added in that order. The mixture is stirred for 1 hour, the temperature gradually rising to 40°C and then dropping. The brown slurry is filtered through a thin pad of celite, and the cake washed with DME in small portions (4 x 2 mL). The filtrate is added to dichloromethane (15 mL). Vigorous stirring results in the formation of yellow coloured precipitate which is collected by vacuum filtration, followed by an ether wash
15 (2 x 2.5 mL). The product is dried under a stream of nitrogen yielding a yellow-tan solid (0.343g, 84%). To this pyrrole complex is added maleimide (0.05g, 0.515 mmol) (or any other "ene", eg maleic anhydride, dimethyl maleate, etc) in acetonitrile. The mixture is allowed to stir at room temperature for 60 min. after which the solvent is removed by vacuum, yielding the exo isomer (0.359g, 64%). The crude material is
20 purified by ion-exchange column (Sephadex-CM C-25, 2 x 10 cm), using NaCl as the mobile phase. The complexes are precipitated by the addition of a saturated sodium tetraphenylborate solution.

The types of cancer which are amenable to treatment by these compounds include those types of cancer which are inherently resistant to conventional

chemotherapy. Typically, these types of cancer are represented by the more common and more aggressive tumour types such as, but not limited to, colon cancer and non small-cell lung cancer.

The compounds of this invention are suitably administered intravenously,
5 although other modes of administration are possible. Pharmaceutically acceptable diluents, adjuvants, carriers and/or excipients may be used in conjunction with the compounds of this invention.

Suitable such pharmaceutically acceptable substances are those within the knowledge of the skilled person and include compounds, materials and compositions
10 deemed appropriate.

Actual dosage levels of the compounds of the invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired response for a particular patient, composition and mode of administration.

The dosage level can be readily determined by the physician in accordance with
15 conventional practices and will depend upon a variety of factors including the activity of the particular compound of the invention to be administered, the route of administration, the time of administration, the rate of excretion of the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

20 The compounds of this invention may also sensitise cancer cells to other methods of treatment. For example, typically these methods include irradiation and treatment with platinum anti-cancer agents, for example cisplatin.

In addition, sensitisation may also be brought about by, for example the use of the plant alkaloids vinblastine and vincristine, both of which interfere with tubulin and

the formation of the mitotic spindle, as well as taxanes and antimetabolites, including 5-fluorouracil, methotrexate and antifolates.

In particular, the compounds of this invention sensitise those cells with deficient p53 activity.

5 When screening for anti-cancer activity as contemplated by the invention, various cancer cell lines may be chosen. These are typically both haematopoietic and solid tumour cell lines with varying p53 status and include: L1210 (murine leukaemia, p53 wildtype), HL60 (human leukaemia, p53 nul), A2780 (human ovarian carcinoma, p53 wildtype), ADDP (cisplatin resistant A2780 cells, p53 mutant), SW480 (human
10 colon carcinoma, p53 mutant), WiDr (human colon carcinoma, p53 mutant), HT29 (human colon carcinoma, p53 mutant), HCT116 (human colon carcinoma, p53 wildtype) and 143B (human osteosarcoma, p53 mutant).

In addition to the methods for screening for anti-cancer activity, the following procedures may be suitably used in the remainder of the screening process. For
15 example, when screening for the ability to abrogate the G₁ and/or the G₂ checkpoint of the cancer cell cycle, the following are suitably used:

Cell cycle method

The cells are fixed in 70% ethanol and stored at - 20°C until analysis is performed (1-2 weeks). After fixing, the cells are pelleted and incubated in PBS
20 containing propidium iodide (40mg/ml) and RNase A (200 mg/ml) for at least 30 min at room temperature. The samples (2 X 10⁴ events) are analysed using a Becton Dickson FACScan, fluorescence is collected in fluorescence detector 2 (FL2), filter 575/30 nm band pass. Cell cycle distribution is assessed using Cell Quest software (Becton Dickson).

Those protein phosphatase inhibitors which show abrogation of either the G₁ or G₂ checkpoint will then be exploited in combination studies with either radiation exposure or chemotherapy drugs incubation. The MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl-tetrazolium bromide) assay is used to determine whether a synergistic, antagonistic or additive effect is induced. The Median Effect method is adopted to mathematically determine the optimal combination index of the treatments chosen (Chou and Talalay, 1984). This method has been extensively used to investigate the cytotoxicity of various drug combinations including cisplatin and D1694 (Ackland et al 1996; 1998). A combination index value less than 1 indicates synergism, a value equal to 1 indicates additivity and a value greater than one indicates antagonism.

Cytotoxicity assay

When screening for the ability to sensitise cancer cells to conventional chemotherapy and irradiation, the following methods are suitably used:

Cells in a subconfluent phase are transferred to 96- well microtitre plates. L1210 cells are plated at a density of 1000 cells/well in 100µl medium, while all other cell lines are plated at a density of 2000-25000 cells/well. The cells are left for 24h prior to treatment to ensure exponential growth has been achieved, 24h after plating (day 0), 100µl of phosphatase inhibitor is added to each well, control wells received 100µl of medium only. Drug exposure time is 72h (day 3). The effect of phosphatase inhibition is tested in triplicate over a concentration range of $1 \times 10^{-3} \text{M}$ - $1 \times 10^{-8} \text{M}$. Growth inhibitory effects are evaluated using the MTT assay and absorbance read at 540 nm. The IC₅₀ is the drug concentration at which cell growth is 50% inhibited based on the difference of optical density on day 0 and day 3 of drug exposure. Cytotoxicity is evaluated using a spectrophotometric assay which determines the percentage of cell

growth following exposure of the cells to various concentrations of the phosphatase inhibitors for a period of 72 hours. The subsequent dose response curve is used to calculate IC_{50} values (the drug concentration at which cell growth is 50% inhibited).

Most drug discovery has focused on the development of new single agents.

- 5 However, in light of the success of combination chemotherapy it is increasingly apparent that successful anticancer treatment of the future will be based upon the discovery of agents which are synergistic in their action. In view of this, the cytotoxicity of phosphatase inhibitors in combination with either radiation, cisplatin, taxanes, antimetabolites or plant alkaloids is examined. As indicated above, calyculin which by
- 10 itself is not cytotoxic, enhances irradiation induced cell death. Similarly abrogation of the G_2 checkpoint by either, caffeine or UCN-01, also enhances the cytotoxicity of γ irradiation in cells with mutant p53 (CA46 and HT-29 cells) (Powell et al., 1995; Russell et al., 1995; Wang et al., 1996). DNA damage induced by irradiation causes both a G_1 and G_2 cell cycle arrest. In p53 mutant cells, the G_1 checkpoint is absent.
- 15 However, following irradiation the cells will still arrest in the G_2 phase, and potentially repair the damage. P53 mutant cells are generally more resistant to conventional chemotherapy and produce more aggressive tumours. Therefore, in p53 deficient cells, DNA damage that is not detected by the G_1 checkpoint will be picked up by the G_2 checkpoint. If the cells are deficient in both of these checkpoints then it is believed that
- 20 the cells will be unable to initiate repair mechanisms and will be more unstable and increasingly susceptible to cell death induced by DNA damage.

Cisplatin is another commonly used anticancer treatment which binds to DNA and produces DNA crosslinks and strand breaks. Cisplatin is particularly useful in the treatment of testicular carcinoma, small cell carcinoma of the lung, bladder cancer, and

ovarian cancer. Repair of cisplatin induced DNA damage is mediated via nucleotide excision repair which is coordinated by p53 activation of Gadd45 (Smith et al., 1994). In this context, it has been suggested that cells that are p53 mutant are more sensitive to cisplatin treatment (Hawkins et al., 1996). A number of researchers have investigated this proposal in p53 mutant cell lines and in p53 mutant tumours, with mixed results. While it is apparent that cisplatin is more cytotoxic in cells lines that are deficient in p53 (induced via papillomavirus) compared to the p53 proficient cells (Hawkins et al., 1996), it is harder to test this hypothesis in tumours and in cisplatin resistant cells as they may have several undefined mutations in their genome which would confound such studies (Herod et al., 1996). Nevertheless, the G₂ abrogator UCN-01 (7-hydroxystaurosporine, a protein kinase inhibitor) has been shown to markedly enhanced the cell-killing activity of cisplatin in MCF-7 cells defective for p53 function (Wang et al., 1996).

The development of chemotherapeutic agents which selectively target p53 mutant cells is desirable since 50% of tumours have either a mutated or deleted p53 gene. Many of these p53 deficient cells and tumours are inherently resistant to conventional chemotherapy and represent the common more aggressive tumour types such as colon cancer, and non-small cell lung cancer. Thymidylate synthase (TS) inhibitors are another class of commonly used anticancer agents. TS catalyses a critical step in the pathway of DNA synthesis by converting dUMP to dTMP by methylation using the co-substrate N⁵,N¹⁰-methylene tetrahydrofolate (CH₂-THF) as a methyl donor. This step is the only *de novo* source of dTMP, which is subsequently metabolised to dTTP exclusively for incorporation into DNA during synthesis and repair (Jackman & Calvert, 1995). Thus, TS is a key regulatory enzyme during the S-phase of the cell cycle.

Lack of dTTP results in DNA damage and ultimately cell death, but the process(es) by which cell death occurs is not clear. TS inhibitors such as fluorouracil, raltitrexed, and LY231514 play a pivotal role in anticancer treatment and are often the first line treatment of many cancers (Peters & Ackland, 1996). We propose that the TS inhibitor

5 Thymitaq (Zarix, Ltd) be used in combination with cantharidin analogues. Thymitaq is a direct and specific TS inhibitor which does not require active transport into the cell nor does it require intracellular activation for its action.


The following examples are not to be construed as limiting on the scope of the invention as indicated above.

10 Example 1


Chemistry

Anhydride modified cantharidin analogues were synthesised by a variety of modified literature procedures, as set out in schemes 1 and 2. These modifications are embodied in the three methods, which depend on the aromaticity of the starting dienes,

15 set out above. The dimethyl ester (3), which was prepared by the application of high pressure, 17kbar, 40°C, 61 hours, as shown in scheme 3.




Scheme 1. a. Furan: maleic anhydride (5:1), diethylether, 2d, RT, 96%; b. H₂ / 10% Pd-C / EtOH; c. p-TosOH, MeOH, chromatography; d. H₂ / 10% Pd-C / Acetone; e. NaBH₄ then HCl.



5

Scheme 2. Reagents and Conditions: f. Furan:maleimide (5:1), diethyl ether, 7d, in dark, 75%, exo product; g. Furan:Maleimide (5:1), diethylether, sealed tube 12h, 90°C, 66%,endo product.

10



Scheme 3. Reagents and Conditions: h.

15 Furan:dimethylmaleate (2:1), CH₂Cl₂, 17 Kbar, 40°C, 61 h, 56%.

Example 2


Development of potent, selective, oxidatively stable, and cell permeable inhibitors of protein Phosphatases 1 and 2A.

Crude natural product extracts have yielded isopalinurin and a series of
 20 cantharidin analogues have been synthesised. In this context, the present inventors have developed the simple cantharidin analogue which is PP1 selective (IC₅₀ = 50mM, with 0% inhibition of PP2A at concentrations ≥1000mM) representing the first small molecule to exhibit selectivity for PP1. Results have indicated that a series of simple


synthetic modification of the cantharidin skeleton also allows the synthesis of a PP2A selective compound (see Figure 1).

The present inventors have previously demonstrated that a facile ring opening of an anhydride is crucial to inhibition of PP2A. This is not possible with c (previous studies with the 7-O, and this analogue indicated considerable hydrolytic stability of the maleimide link). It is also interesting to note that endothal thioanhydride is three fold more potent than cantharidin, with the S atom being an important factor. It is thus envisaged that the 7-S group presents itself to the active sites metals and the N-H of the maleimide occupies the hydrogen bond cavity normally reserved for the 7-O substituent cantharidin.


Structure of cantharidin and selective analogues



(a)



(b)




(c)

- (a) Shows structure of cantharidin;
- (b) Shows PP1 selective analogue; and
- (c) Shows PP2A selective analogue. In the case of panel (c) $IC_{50} \sim 25mM$.

On the basis of these results and previous experience in our laboratory (synthesis and molecular modelling of cantharidin inhibitors at PP1 and PP2A), we have designed a series of analogues which are more active and selective, whilst retaining the desirable properties of stability and cell permeability.

The synthetic pathways to these analogues are shown in schemes 1-3. Each scheme allows for modification of the basic skeleton, and in some cases the insertion of beneficial feature that were present in the more complex natural toxin(s) (eg okadaic

acid, calyculin, microcystin, etc). The inclusion of these features is designed to provide enhanced selectivity and potency.




10 Example 3

Synthetic development of a series of PP1 and PP2A analogues of cantharidin.

- (i) Diels-Alder addition (maleic anhydride) and subsequent manipulations of X;
 (ii) Diels-Alder addition (substituted maleic anhydrides), introduction and manipulation of Z (Z = hydrophobic tail; eg long chain nitrile: cf Calyculin A, long chain terminating
 15 in a spiro acetal: cf Tautomycin, Okadaic acid; long chain terminating in an aromatic ring: cf Adda in Microcystin-LR; (iii) stereospecific ring opening of the anhydride allowing further manipulations of the newly released functional groups (see scheme 2).


In this instance we have developed synthetic protocols in our laboratory that allow the facile assembly of these analogues. Biological evaluation and molecular
 20 modelling of the most active molecules will allow compounds to be evaluated.

Additional modification to the basic structure can be obtained as exemplified below.



Example 4

A specific example of one class of cantharidin analogue that shows promise as a selective inhibitor of protein phosphatases 1 and 2A.



Example 5

Stereospecific route towards 7-azabicyclo [2.2.1] heptanes

15 We have shown that the introduction of the bridgehead nitrogen improves the potency, selectivity and stability of similar analogues, the above pathway has been developed to further improve the bio-activity of these analogues. The synthetic routes alluded to herein may allow the rapid assembly of the target molecules.

Those agents which meet the requirements of being stable, specific, potent, and
20 membrane permeable protein phosphatase inhibitors are screened for their anti-cancer activity.

Example 6

Biochemistry

All synthesised compounds were tested for their ability to inhibit protein phosphatases 1 and 2A. Initial investigations were carried out at 100 mM. Promising analogues were then assayed in triplicate for estimation of IC₅₀ values.

Protein phosphatase 1 and 2A were partially purified from chicken skeletal muscle essentially as described by Cohen. Protein phosphatase activity was measured at 37°C in 50 mM Tris-HCl buffer (pH 7.4), 0.1 mM EDTA, 5 mM caffeine, 0.1% 2-mercaptoethanol and 1 mg/ml bovine serum albumin using 30 mg [³²P]-phosphorylase as substrate. The total assay volume was 30 ml. The assay conditions were restricted to 20% dephosphorylation to ensure linearity and inhibition of protein phosphatase activity was determined by including cantharidin or its analogues at the required concentrations in the reaction buffer. Reactions were terminated by the addition of 0.1 ml ice cold 20% trichloroacetic acid. Precipitated protein was pelleted by centrifugation and the radioactivity in the supernatant measured by liquid scintillation counting. Data is expressed as the percentage inhibition with respect to a control (absence of a competing compound) incubation.

Example 7

Screening various PP1 and PP2A inhibitors for anti-cancer activity

(a) Cytotoxicity of protein phosphatase inhibition:

Those PP1 and PP2A inhibitors which fulfil the requirements detailed above were tested in various cancer cell lines. The cell lines chosen for study included both haematopoietic and solid tumour cell lines with varying p53 status and include:

L1210 (murine leukaemia, p53 wildtype),
HL60 (human leukaemia, p53 nul),
A2780 (human ovarian carcinoma, p53 wildtype),
ADDP (cisplatin resistant A2780 cells, p53 mutant),
5 SW480 (human colon carcinoma, p53 mutant),
WiDr (human colon carcinoma, p53 mutant).
HT29 (human colon carcinoma, p53 mutant)
HCT116 (human colon carcinoma, p53 wildtype)
143B (human osteosarcoma, p53 mutant)

10 Anti-cancer screening of the protein phosphatase inhibitors is assessed using the MTT assay. This assay determines cell viability by the ability of mitochondrial dehydrogenase to produce formazan crystals from 3-(4,5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide. The viable cell number/well is directly proportional to the production of formazan, which following solubilization, can be measured
15 spectrophotometrically (540nm). This technique is also used by the National Cancer Institute to screen for new anticancer agents.

As described herein a number of cantharidin analogues have been synthesised and tested for their anticancer activity in nine cancer cell lines using the MTT assay after 72 h exposure. These new analogues are shown in Figure 2 and have been designated
20 MK-1 through to MK-9. The cytotoxicity (IC_{50}) of these cantharidin analogues is shown in Table 1 and Figure 3. In summary, the MK-1 analogue did not show any significant cytotoxicity in any of the cell lines tested ($IC_{50} > 1000\mu M$). Only marginal cytotoxicity across all cell lines tested was observed for MK-3 (IC_{50} 247 to $> 1000\mu M$), MK-7 (IC_{50} 180-367 μM) and MK-8 (IC_{50} 173-385 μM). Greater cytotoxicity was observed with

TABLE 1

IC₅₀ values of tumour cell lines after 72 h continuous exposure to cantharidin and cantharidin analogues.

Tumour type	Cell line	p53 status	IC ₅₀ (mean ± SE) after 72h continuous exposure (μM)								
			Cantharidin	MK-1	MK-2	MK-3	MK-4	MK-5	MK-7	MK-8	MK-9
Murine Leukaemia	L1210	wt	18 ±	>1000	185 ± 51	647 ± 132	680 ± 97	>1000	367 ± 37	337 ± 19	192 ± 56
	HL60	nul	13 ±	>1000	177 ± 3	247 ± 55	393 ± 103	323 ± 13	293 ± 7	297 ± 3	133 ± 9
Human Ovarian	A2780	wt	±	>1000	157 ± 9	317 ± 17	333 ± 55	567 ± 109	357 ± 102	313 ± 61	187 ± 9
Human Ovarian	ADDP	mt	12 ± 0.8	>1000	183 ± 17	>1000	275 ± 56	260 ± 40	210 ± 18	208 ± 19	233 ± 23
Human Osteosarcoma	143B	mt	10.2 ± 1.2	>1000	248 ± 29	665 ± 225	450 ± 50	>1000	327 ± 67	385 ± 43	223 ± 44
Human Colon	HCT116	wt	12 ±	>1000	160 ± 10	>1000	78 ± 7	143 ± 23	180 ± 20	173 ± 22	107 ± 12
Human Colon	HT29	mt	6.4 ± 0.7	>1000	183 ± 20	530 ± 112	14 ± 0.3	28 ± 1	297 ± 58	373 ± 54	205 ± 13
Human Colon	WiDr	mt	6.1 ± 0.5	>1000	198 ± 53	620 ± 31	15 ± 3	31 ± 10	320 ± 20	367 ± 44	190 ± 35
Human Colon	SW480	mt	17.5 ±	>1000	155 ± 9	444 ± 27	88 ± 5	247 ± 14	333 ± 22	353 ± 20	147 ± 14

wt = wildtype, mt = mutant.

MK-2 (IC_{50} 157-248 μ M) and MK-9 (IC_{50} 107-233 μ M) which was also consistent across the nine cell lines. The greatest cytotoxicity was observed with the MK-4 and MK-5 analogues, however, the magnitude of this response was cell line dependent. In this context, MK-4 and MK-5 were selectively more cytotoxic in the human colon cancer cell lines (IC_{50} 14-88 μ M; 28-247 μ M) compared with leukaemia (IC_{50} 393-680 μ M; 323-
5 >1000 μ M) ovarian (IC_{50} 275-333 μ M; 260-567 μ M), and osteosarcoma (IC_{50} 450 μ M; >1000 μ M) cells respectively.

(b) Abrogation of cell cycle checkpoints:

The ability of the protein phosphatase inhibitors to abrogate the G_1 or G_2
10 checkpoint of the cell cycle may be determined by cell cycle analysis using flow cytometry. Briefly, asynchronous cell cultures are harvested 18h after 6Gy irradiation and/or 12h incubation with the protein phosphatase inhibitor. Depending upon the p53 status of the cell line, radiation treatment alone will induce arrest in either G_1 and/or G_2 phase of the cell cycle.

15 Data shown in Table 2 and Figure 4 show the cell cycle response of L1210, HL60, HT29 and HCT116 cells to cantharidin and the new cantharidin analogues MK-2 and MK-4 after 12h exposure. In summary, cantharidin and MK-2 produced a similar response and induced G_2 arrest in all four cell lines tested. MK-4 also induced G_2 arrest but only in L1210, HL60 and HCT116 cells. In HT29 cells, MK-2 induced G_1 cell cycle
20 arrest. The magnitude of the cell cycle arrest induced by these drugs directly correlated with their cytotoxicity in the respective cell lines. The ability of the parent compound cantharidin to inhibit cell growth is also shown (IC_{50} 6.1-18 μ M). The cytotoxicity of the cantharidin is greater than for its analogues. Interestingly, cantharidin also showed slight selectivity towards the colon cancer cells.

TABLE 2

Cell Cycle Analysis

Cell Cycle Distribution (percentage of total) of tumour cell lines 12h after cantharidin or cantharidin analogue treatment.

Method : Flow Cytometry of Propidium Iodide stained cells.

Agent	L1210 cells					HL60 cells					HCT116 cells					HT29 cells				
	μ M	sub G ₁	G ₁	S	G ₂ +M	sub G ₁	G ₁	S	G ₂ +M		sub G ₁	G ₁	S	G ₂ +M		sub G ₁	G ₁	S	G ₂ +M	
Cantharidin	0	0.5	47.4	34.3	19.4	1.9	45.5	25.8	28.2		6.5	43.3	14.6	36.4		11.1	45.3	8.0	36.0	
	1	0.5	45.8	33.7	21.6	1.5	44.0	26.1	29.7		2.2	39.9	17.2	41.9		9.0	46.2	7.8	37.4	
	5	0.6	46.5	32.6	21.9	1.7	41.4	27.7	30.6		2.9	39.9	16.8	41.8		4.0	47.4	9.3	39.8	
	10	0.5	49.1	33.0	18.9	1.7	41.8	27.5	30.4 G ₂ arrest		6.2	38.0	14.9	42.0		2.8	42.7	14.6	40.3 G ₂ arrest	
	50	1.9	22.0	27.8	50.6 G ₂ arrest	19.3	16.2	31.6	34.7 Cell Death		11.1	25.1	17.8	48.1 G ₂ arrest		15.1	46.0	14.7	26.0 Cell Death	
MK-2	0	0.4	40.1	28.4	32.1	2.1	45.6	21.0	32.6		4.7	44.2	13.7	36.8		6.0	46.4	9.3	37.5	
	50	0.3	42.7	26.2	31.7	1.8	44.1	23.8	31.4		1.3	47.2	13.8	37.4		9.4	45.3	7.6	37.1	
	100	0.6	45.2	22.4	32.4	1.8	43.3	23.6	32.4		1.7	47.2	16.0	34.5		3.6	49.8	8.2	37.6	
	250	2.4	46.7	14.3	36.7	3.2	37.7	23.8	36.4 G ₂ arrest		1.4	52.8	11.1	34.3		4.2	41.4	11.2	42.5 G ₂ arrest	
	500	3.9	26.3	10.1	60.0 G ₂ arrest	18.8	17.8	21.6	43.1 Cell death		2.5	39.4	11.3	46.5 G ₂ arrest		5.2	44.5	15.4	33.6 S-phase	
MK-4	0	0.8	42.0	26.9	31.7	2.3	49.9	21.6	27.4		4.1	44.0	12.5	39.4		5.5	45.7	7.4	41.4	
	50	0.5	42.0	26.9	32.0	1.9	44.7	22.3	32.3		4.5	43.9	11.4	40.7		4.7	51.4	12.3	31.6	
	100	0.4	43.2	25.4	32.5	2.5	45.3	22.6	30.6		2.0	41.4	13.6	44.1		6.0	52.3	12.5	29.4	
	250	0.5	45.7	24.6	30.5	6.0	40.0	23.0	32.0		3.9	36.2	14.1	46.9		7.0	53.2	11.9	27.6	
	500	1.1	47.5	18.6	33.9 Slight Δ	6.1	27.8	22.8	44.4 G ₂ arrest		9.6	29.0	15.7	46.5 G ₂ arrest		3.4	53.7	14.1	29.1 G ₁ arrest	

If the protein phosphatase inhibitor abrogates the G_2 checkpoint then the cells will not arrest in the G_2 phase of the cell cycle and the cells will continue through the cell cycle and accumulate in the G_1 phase of the cell cycle only. Similarly if the protein phosphatase inhibitors abrogates the G_1 checkpoint then the cells will not arrest in the G_1 phase of the cell cycle and accumulate in the G_2 phase of the cell cycle only. Cell cycle analysis using propidium iodide labelling of DNA has been used extensively in our laboratory to assess the effect of specific anticancer agents that induce S-phase cell cycle arrest and apoptotic cell death (Sakoff, Ackland and Stewart, 1998). Experiments were performed on a Becton Dickinson FACScan and using Cell Quest software.

Data shown in Table 3 and Figure 5 show the cell cycle response of L1210, HL60, HT29 and HCT116 cells. The cells were treated with 6Gy of radiation and then treated with cantharidin 6h later. The ability to abrogate cell cycle arrest was assessed 12h after the addition of the drugs. Cantharidin and MK-2 both abrogated radiation induced G_1 arrest in all cell lines. MK-4 also abrogated G_1 arrest in L1210, HL60 and HCT116 cells. In HT29 cells, MK-4 induced abrogation of the G_2 checkpoint. It is important to note that the exposure of HT29 cells to MK-4 induced the greatest cytotoxicity (IC_{50} 14 μ M) as determined by the MTT assay. Not surprisingly, the ability to abrogate the G_2 checkpoint was more lethal than the ability to abrogate the G_1 checkpoint.

(c) Combination studies:

The cell lines listed above are exposed continuously to cisplatin and the phosphatase inhibitor in various drug ratio combinations for 72h and then assayed for cytotoxicity. Similarly, the cells are exposed to 8 Gy of radiation and incubated with the phosphatase inhibitor and assessed for cytotoxicity at 72 h.

TABLE 3

Checkpoint Abrogation

Cell Cycle Distribution (percentage of total) of tumour cell lines 18h after 6Gy of radiation and 12h after cantharidin or cantharidin analogue treatment.

Method : Flow Cytometry of Propidium Iodide stained cells.

Agent	L1210 cells					HL60 cells					HCT116 cells					HT29 cells				
	μ M	sub G ₁	G ₁	S	G ₂ +M	sub G ₁	G ₁	S	G ₂ +M	sub G ₁	G ₁	S	G ₂ +M	sub G ₁	G ₁	S	G ₂ +M			
Cantharidin	0	1.6	25.3	35.8	38.8	6.6	5.3	3.2	85.3	4.9	26.8	8.7	60.1	5.9	40.7	9.2	44.7			
	1	1.6	27.2	25.6	37.5	6.2	5.2	3.0	85.8	4.2	26.1	13.8	58.2	16.6	35.2	10.6	38.2			
	5	2.4	25.8	31.9	41.5	4.4	5.7	3.5	86.8	4.0	23.6	10.4	63.3	5.3	38.6	10.6	46.3			
	10	3.4	24.9	29.4	43.7	5.3	5.6	4.3	85.1	4.2	25.7	9.4	62.2	6.4	21.1	12.3	60.8			
	50	4.9	4.1	15.6	77.4	G ₁ abrogation	14.3	10.2	11.3	64.9	Cell Death	12.0	12.2	15.6	63.3	G ₁ abrogation	14.7	23.0	20.7	43.1
MK-2	0	1.6	16.4	31.1	52.1	7.0	5.9	2.2	85.1	3.7	30.8	7.9	57.2	17.3	31.8	8.7	41.3			
	50	4.0	19.0	27.8	50.1	5.9	6.1	2.8	85.5	3.3	32.8	6.3	57.3	10.3	35.4	8.8	44.7			
	100	3.5	18.4	23.0	55.8	5.5	6.1	3.3	85.4	3.1	29.9	7.2	59.6	3.5	40.6	9.0	45.9			
	250	6.9	11.2	10.0	71.9	8.1	5.4	2.8	83.9	6.2	23.9	4.3	65.4	2.7	24.9	12.3	59.4			
	500	5.4	3.4	2.9	88.4	G ₁ abrogation	11.8	4.4	4.1	80.0	Cell Death	6.4	15.4	4.9	73.0	G ₁ abrogation	8.8	24.1	20.4	45.2
MK-4	0	1.9	20.2	29.7	50.0	8.7	5.7	2.0	83.9	10.3	31.4	6.2	52.1	7.0	35.1	9.3	48.4			
	50	1.8	21.2	28.5	50.3	8.9	6.2	2.8	82.3	6.3	26.7	5.8	61.3	6.8	28.9	16.4	48.4			
	100	2.4	22.0	27.4	49.7	9.8	6.2	3.4	80.8	3.3	18.4	9.7	69.3	6.3	33.3	17.2	43.3			
	250	3.1	21.2	24.6	52.7	9.3	5.8	3.1	82.2	8.2	16.3	8.2	67.8	10.3	35.2	17.3	36.5			
	500	5.0	18.2	16.0	61.8	G ₁ abrogation	11.6	5.2	5.4	78.2	Cell Death	14.9	13.1	10.6	61.9	G ₁ abrogation	3.9	39.4	19.2	37.7

Data shown in Figures 6-9 shows the results of combination studies utilising the Median Effect Method in HT29 and HCT116 human colon cells. This method tests the cytotoxicity of various drug combinations from which a combination index can be calculated. A value of greater than one indicated antagonism, a value equal to 1 indicates
5 additivity, while a value less than one indicates synergism. The HT29 and HCT116 cell lines were chosen as they have differing p53 status and they represent the tumour types that responded the greatest to cantharidin and its analogues.










The data show that the simultaneous combination of cisplatin and MK-4 in both HCT116 and HT29 cells was additive and not synergistic using drug molar ratios of 1:1,
10 10:1 and 1:10. An additive response indicated that the drugs were mediating their effects via two separate biochemical pathways. The simultaneous combination of taxotere and MK-4 in HT29 cells was also additive using drug molar ratios of 1:10, 1:100, 1:1000 (Taxotere: MK-4). However, this drug combination of taxotere and MK-4 induced a synergistic response in HCT116 cells. A synergistic response indicates that the two
15 drugs were interacting in such a way as to enhance the overall cytotoxic response and to induce "more than the additive" response of each individual agent. Consequently, the addition of subtoxic levels of MK-4 clearly enhanced the cytotoxicity of taxotere.

Example 8

Results and Discussion

20 Anhydrides and simple analogues were synthesised according to literature procedures (Eggelte et. al: 1973), and then subjected to a PP1 and PP2A bio-assay (see biochemistry) to determine their ability to inhibit these enzymes. The results of initial screening at 100 mM are shown in Table 4, along with IC₅₀ values in some instances.

Table 4. The inhibition of protein phosphatase 1 and 2A by anhydride modified cantharidin analogues.

Compound	Inhibition of PP1 (%)	Inhibition of PP2A (%)	Selectivity PP2A/PP1
 1	90 IC ₅₀ 2.4 μM	97 IC ₅₀ 2.1 μM	0.875
 2	ND	95	
 3	46 IC ₅₀ 50 μM	6 IC ₅₀ >10,000 μM	>200
 4	13	11	
 5	15	8	
 6	9	11	
 7	ND	21	
 8	ND	15	
 9	ND	4	

Of the compounds listed in Table 4, only 1 and 2 show any significant inhibition of PP2A, at 97% and 95% respectively (with little selectivity apparent for either enzyme). Interestingly the bioisosteric replacement of the anhydride oxygen atom of 1 results in a complete loss of inhibition. Indeed no modification of the cyclic anhydride, is tolerated, and consequently results in no inhibition of PP2A.

Previously we have shown that analog 2 undergoes a rapid conversion to the dicarboxylic acid under assay conditions. We thus examined the stability of the non-active analogues (in Table 4) and found that they were stable under assay conditions showing no decomposition, in fact 5 can be synthesised via the Diels-Alder reaction in water (Eggelte et al; 1973).

In all instances, the corresponding dicarboxylic acid derivatives display lower inhibitory values at PP2A (Tables 5 and 6). Even though the anhydrides undergo a facile ring opening to the dicarboxylic acids, the original conformation presented at the active site must also play a role in determining the overall level of inhibition. Consequently, we believe that the conformation of anhydride carbonyl groups is more favourable for inhibition (essentially only one conformation presented at the active site), than that of the dicarboxylic acid (four possible minimum energy conformations, data not shown).

In an attempt to determine the feasibility of anhydride opening via nucleophilic attack from Tyr272, we conducted a series of model experiments in which 2 was allowed to stand in a chloroform solution of phenol. This mixture was examined periodically by ¹H NMR spectroscopy and showed the growth of a new species over a period of time (ca 10 days). Further analysis indicated the presence of a phenolate ester of norcantharidin (scheme 4). Consequently, a metal assisted or nucleophilic attack under physiological conditions represents a possible mode of assisted ring opening with the anhydride held in

Tabl 5 . Effects of anhydride to dicarboxylic acid on the inhibition of PP2A.












Entry	Anhydride	Inhibition (%)	Carboxylic acid	Inhibition (%)
1		97 (This work)	 10	80
2		92-95		92-95
3		48		17

TABLE 6 Inhibition of PP1 and PP2A by selected cantharidin analogues.

Entry	Compound	Inhibition of PP1 (%)	Inhibition of PP2A (%)	Selectivity PP2A/PP1
1		90 (IC ₅₀ 2.4 μM)	97 (IC ₅₀ 2.1 μM)	0.875
2		46 (IC ₅₀ 50 μM)	6 (IC ₅₀ >10000 μM)	>200
4		3	3	Not determined
5		15	69	Not determined

a favourable conformation within the active site. In turn the resultant diacid rapidly binds in a more favourable manner.



Scheme 4

The results presented herein indicate that cantharidin analogues, via anhydride opening are more potent inhibitors of PP2A. Analogues in which the anhydride moiety has been modified preventing a facile ring opening (except where otherwise indicated) are extremely poor inhibitors of PP2A (Tables 5 and 6).

However, the most interesting result reported herein (see table 4) is the selective inhibition of PP1 by the dimethyl ester (3). Simple diesterification of 2 has completely reversed the previously reported PP2A selectivity (ca 10 fold) of norcantharidin for PP2A to yield selective small synthetic molecule for the inhibition of either PP1 or PP2A. Again this suggests that presentation of a diacid moiety to the active site is crucial for the inhibition of PP2A. No such restrictions are apparent with the limited structure activity data for PP1.

A synthetic inhibitor such as 3 represents a significant advance on the currently widespread inhibitors of PP1 and PP2A.

In conclusion, the present inventors have demonstrated that a facile ring opening of the anhydride moiety is relevant for inhibition at PP2A. Also, that modification of the dicarboxylic acid moiety gives rise to a PP1 selective compound.

The above describes some embodiments of the present invention. Modifications obvious to those skilled in the art can be made without departing from the scope of this invention.

Industrial Applicability

It should be clear that the present invention will find light applicability, especially in the medical and veterinary fields.


REFERENCES

- Walsh A H, Chen A T, Honaken R E, *FEBS Lett.*, **1997**, *416*, 230
- Roberge M, Tudan C, Hung SMF, Harder KW, Jirik FR, and
5 Anderson H *Cancer Research* **1994**, *54*, 6115-6121.
- McCluskey, A; Taylor, C; Quinn, R J; Suganuma, M; Fujiki, H; *Bioorg. Med. Chem. Lett.*, **1996**, *6*, 1025.
- McCluskey A, Keane M A, Sim A T R, *J. Med. Chem.* **1998**, submitted.
- 10 Enz, A; Zenke, G; Pombo-Villar; *Bioorg. Med. Chem. Lett.*, **1997**, *7*, 2513; and Sodeoka, M; Baba, Y; Kobayashi, S; Hirukawa, N; *Bioorg. Med. Chem. Lett.*, **1997**, *7*, 1833.
- Cohen, P; Cohen, P T W; *J. Biol. Chem.*, **1989**, *264*, 21435.
- Cohen, P; "The Structure and Regulation of Protein
15 Phosphatases" Raven Press: New York, **1990**, p230-235.
- Shenolinkar, S; Nairn, A C; *Adv. Second Messenger Phosphoprotein Res.*, **1991b**, *23*, 1.
- Krebs, E G; *Angew. Chem., Int. Ed. Engl.*, **1993**, *32*, 1122.
- Fischer, E; *Angew. Chem., Int. Ed. Engl.*, **1992**, *32*, 1130.
- 20 Tachibana, K; Scheuer, P J; Tsukitani, Y; Kikuchi, H; Van Engen, D; Clardy, J; Gopichand, Y; Schmitz, F J; *J. Am. Chem. Soc.*, **1981**, *103*, 2469.
- Cheng, X-C; Kihara, T; Kusakabe, H; Magae, J; Kobayashi, Y; Fang, R-P; Ni, Z-F; Shen, Y-C; Ko, K; Yamaguchi, I;
- 25 Isono, K; *J. Antibiot.*, **1987**, *40*, 907.
- Botes, D P; Tuinman, A A; Wessels, P L; Viljoen, C C; Kruger, H; Williams, D H; Santikarn, S; Smith, K J; Hammond, S J; *J. Chem. Soc. Perkin Trans I*, **1984**, 2311.

- Harada, K-I; Matsuura, K; Suzuki, M; Oka, H; Watanabe, M
F; Oishi, S; Dahlem, A M; Beasley, V R; Carmichael, W W;
J. Chromatog., **1988**, *448*, 275.
- Honaken, R E; *FEBS Lett*, **1993**, *330*, 283.
- 5 Matszawa, S; Suzuki, T; Suzuki, M; Matsuda, A; *FEBS Lett.*,
1994, *356*, 272.
- Wang, G-S; *J. Ethnopharmacol.*, **1989**, *26*, 147.
- Cavill, G W K; Clark, D V; *Naturally Occuring Insecticides*
(M. Jacobson and D G Crosby, Eds), Marcel Dekker, New York,
10 **1971**, 271.
- Oaks, W W; DiTunno, J F; Magnani, T; Levey, H A; Mills, L
C ; *A.M.A. Arch. Int. Med.*, **1960**, *105*, 106.
- Goldfarb, M T; Gupta, A K ; Sawchuk, W S; *Dermatologic*
Clinics, **1991**, *9*, 287.
- 15 a. Schmitz, D G; *J. Vet. Intern. Med.*, **1989**, *3*, 208.
- Polettini, A; Crippa, U; Ravaggi, A; Saragoni, A.;
Forensic. Sci. Int., **1992**, *56(1)*, 37.
- Li, Y-M; Casida, J E; *Proc. Natl. Acad. Sci. USA*, **1992**,
89, 11867.
- 20 McCluskey, A; Taylor, C; Quinn, R J; Suganuma, M; Fujiki,
H; *Bioorg. Med. Chem. Lett.*, **1996**, *6*, 1025.
- Eggelte, T A; de Koning, H; Huisman, H O; *Tetrahedron*,
1973, *29*, 2445; 3 see: Tamura, Y; Imanishi, K; Miki, Y;
Ikeda, M; *Synthesis*, **1977**, 559; 5 & 9 see: Kwart, H;
- 25 Burchuk, I; *J. Am. Chem. Soc.*, **1952**, *74*, 3094.
- Goldberg, J; Huang, H-B; Kwon, Y-G; Greengard, P; Nairn, A
C; Kuriayan, J; *Nature*, **1995**, *376*, 745.
- Quinn, R J; Volter, K; Embury, K J, unpublished results.


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A cell permeable inhibitor of protein phosphatase, said inhibitor being an anhydride modified cantharidin analogue.
2. An inhibitor according to claim 1, wherein the phosphatase is phosphatase 1 and/or phosphatase 2A.
3. An inhibitor according to claim 1 or 2 wherein the anhydride modified cantharidin analogue is oxidatively stable.
4. A compound of the formula:



10

wherein R_1 and R_2 are H, aryl or alkyl; X is O, N or S; Y is O, S, SR, NH, NR, CH_2OH , CH_2OR ; R is alkyl or aryl; A and B are H or CH_3 ; W and Z are $CHOH$ or $C=O$ and R_1 and R_2 can cyclise to form a ring as follows:



15 wherein R_3 and R_4 are H, aryl or alkyl.

5. A compound according to claim 3, wherein the aryl group is phenyl or naphthyl and wherein the aryl group is attached via a carbon spacer of between 6 and 10 carbon atoms.
6. A compound according to claim 3 or claim 4, wherein the alkyl group is C_1 - C_{10} .

7. A process for producing anhydride modified cantharidin analogues for use in the treatment of cancer or for the sensitising cancer cells to one or more cancer treatments comprising the step of reacting a diene with an ene.
8. A process according to claim 7 further comprising hydrogenation of the adduct
5 of the diene and the ene.
9. A process according to claim 7 or 8 further comprising ring opening of the adduct of the diene and the ene.
10. A process for producing anhydride modified cantharidin analogues, said process including the steps of:
10 dissolving a diene in a suitable solvent and adding to the resultant solution an ene.
11. A process for producing anhydride modified cantharidin analogue, said process including the steps of:
dissolving a furan in a suitable solvent and adding to the resultant solution an
15 ene;
incubating the solution at a temperature and for a time sufficient to form a precipitate; and
collecting the precipitate and recrystallising the analogue.
12. A process for producing anhydride modified cantharidin analogue, said process
20 including the steps of:
mixing thiophene and maleic anhydride at room temperature in a suitable solvent;

compressing the mixture at a temperature and pressure sufficient to facilitate a reaction to take place; and

purifying the analogue.

13. A method of treating cancer which method comprises administering to a patient
5 in need of such treatment, an effective amount of an inhibitor according to any one of claims 1 to 3 or a compound according to any one of claims 4 to 6, together with a pharmaceutically acceptable carrier, diluent and/or excipient.

14. A method according to claim 13, wherein the cancer is inherently resistant to conventional chemotherapy.

10 15. A method according to claim 13 or claim 14, wherein the cancer is colon cancer or non small-cell lung cancer.

16. A method according to any one of claims 13 to 15, wherein the inhibitor or the compound is administered intravenously.

17. A method of sensitising cancer cells to at least one method of treating cancer,
15 which method of sensitising comprises administering to a patient in need of such treatment, an effective amount of an inhibitor according to any one of claims 1 to 3 or a compound according to any one of claims 4 to 6, together with a pharmaceutically acceptable carrier, diluent and/or excipient.

18. A method according to claim 17, wherein the at least one cancer treatment is
20 selected from treatments involving irradiation and anti-cancer agents.


19. A method according to claim 17 or claim 18, wherein the cells have deficient p53 activity.

20. A method of treating cancer which method comprises:
- administering to a patient in need of such treatment, an effective amount of an anhydride modified cantharidin analogue of any one of claims 1 to 3 or a compound according to any one of claims 4 to 6 to sensitise cells of the patient to one or more
- 5 cancer treatments; and
- utilising the one or more cancer treatments.
21. A method of screening compounds for use in sensitising cancer cells to at least one method of treating cancer, and comprising:
- screening for anti-cancer activity; and
- 10 screening for ability to abrogate either the G₁ or the G₂ checkpoint of the cancer cell cycle.
22. A method according to claim 21 further comprising the step of screening for the ability of the compounds of sensitise cancer cells to one or more cancer treatments.
23. A method according to claims 21 or 22 wherein the one or more cancer
- 15 treatments are selected from treatments involving cisplatin, irradiation, taxanes and antimetabolites.
24. A method according to any one or claims 21 to 23 wherein the screening is conducted on haematopoietic cells or solid tumour cells, having varying p53 activity.
25. A method according to claim 24, wherein the cells are selected form the group
- 20 consisting of L1210 (murine leukaemia, p53 wildtype), HL60 (human leukaemia, p53 nul), A2780 (human ovarian carcinoma, p53 wildtype), ADDP (cisplatin resistant A2780 cells, p53 mutant), SW480 (human colon carcinoma, p53 mutant), WiDr (human


colon carcinoma, p53 mutant), HT29 (human colon carcinoma, p53 mutant), HCT116 (human colon carcinoma, p53 wildtype) and 143B (human osteosarcoma, p53 mutant).

26. A compound selected from a group comprising compounds (a) to (k) below:


(a)




(b)




(c)




(d)




(e)




(f)




(g)




(h)




(i)




(j)




(k)




(l)



(m)



(n)



27. Use of an inhibitor according to claim 1 or claim 2, or a compound according to any one of claims 3 to 5 for the manufacture of a medicament for the treatment of cancer.

5 28. Use according to claim 27, wherein the cancer is colon cancer or non small-cell lung cancer.


29. Use according to claim 27 or claim 28, wherein the medicament is administered intravenously.

- Cohen, P; Alemany, S.; Hemmings, B A; Resink, T J; Stralfors, P and Tung, H Y L in *Methods in Enzymology* (Ed. J D Corbin and R A Johnson) 1988, 159, 390. Academic Press (London).
- Hardie, DG; Haystead TAJ; Sim ATR; Protein Phosphorylation, in methods in
5 enzymology, in press. *Enz. A*; Zenke, G; Pombo-Villar; *Bioorg. Med. Chem. Lett.*,
1997, 7, 2513.
- Sodeoka, M; Baba, Y; Kobayashi, S; Hirukawa, N; *Bioorg. Med. Chem. Lett.*, 1997, 7,
1833.
- Durfee T., et al., (1993). The retinoblastoma protein associates with the protein
10 phosphatase type 1 catalytic subunit. *Genes Dev.* 7, 555-569.
- Ghosh, S. et al. (1996). Okadaic acid overrides the S-phase checkpoint and accelerates
progression of G2-phase to induce premature mitosis in Hela cells. *Exp. Cell Res.* 227:165-
169.
- Herwig, S., and Strauss, M. (1997). The retinoblastoma protein: a master regulator of
15 cell cycle, differentiation and apoptosis. *Eur.J.Biochem.* 246:581-601.
- Jackman, AL and Calvert. AH (1995). Folate-based thymidylate synthase inhibitors as
anticancer drugs. *Ann.Oncol.* 6:871-881, 1995.
- Kawamura K-I, Grabowski D, Weizer K, Bukowski R, and Ganapathi R (1996).
Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase
20 inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of
apoptosis in human tumour cells. *Br. J. Cancer* 73: 183-188.
- Lazzereschi, D. et al. (1997). The phosphatase inhibitor okadaic acid stimulates the

- TSH-induced G1-S phase transition in thyroid cells. *Exp. Cell Res.* 234:425-433.
- Nakamura K. and Antoku S. (1994). Enhancement of X-ray cell killing in cultured mammalian cells by the protein phosphatase inhibitor calyculin A. *Cancer Res* 54:2088-20990.
- 5 O'Connor PM (1996). Cell cycle checkpoints: Targets for anti-cancer therapy. *Anti-Cancer Drugs* 7(sup 3): 135-41.
- O'Connor PM (1997). Mammalian G1 and G2 phase checkpoints. *Cancer Surveys* 29:151-182.
- Peters GJ and Ackland SP (1996). New antimetabolites in preclinical and clinical
10 development. *Exp. Opin. Invest. Drugs* 5, 637-679.
- Schönthal A (1992). Okadaic acid - a valuable new tool for the study of signal transduction and cell cycle regulation? *New Biol.* 4, 16.
- Stein, G.S. et al. (1998). The molecular basis of cell cycle and growth control. Wiley-Liss Publishers, New York.
- 15 Yamashita K., et al (1990). Okadaic acid, a potent inhibitor of type 1 and type 2A protein phosphatases, activates cdc2/H1 kinase and transiently induces a premature mitosis-like state in BHK21 cells. *EMBO J.* 9: 4331-4338.


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A cell permeable inhibitor of protein phosphatase, said inhibitor being an anhydride modified cantharidin analogue.
2. An inhibitor according to claim 1, wherein the phosphatase is phosphatase 1 and/or phosphatase 2A.
3. An inhibitor according to claim 1 or 2 wherein the anhydride modified cantharidin analogue is oxidatively stable.
4. A compound of the formula:



wherein R_1 and R_2 are H, aryl or alkyl; X is O, N or S; Y is O, S, SR, NH, NR, CH_2OH , CH_2OR ; R is alkyl or aryl; A and B are H or CH_3 ; W and Z are $CHOH$ or $C=O$ and R_1

- and R_2 can cyclise to form a ring as follows:



wherein R_3 and R_4 are H, aryl or alkyl.

5. A compound according to claim 3, wherein the aryl group is phenyl or naphthyl and wherein the aryl group is attached via a carbon spacer of between 6 and 10 carbon atoms.
6. A compound according to claim 3 or claim 4, wherein the alkyl group is C_1 - C_{10} .

7. A process for producing anhydride modified cantharidin analogues for use in the treatment of cancer or for the sensitising cancer cells to one or more cancer treatments comprising the step of reacting a diene with an ene.
8. A process according to claim 7 further comprising hydrogenation of the adduct
5 of the diene and the ene.
9. A process according to claim 7 or 8 further comprising ring opening of the adduct of the diene and the ene.
10. A process for producing anhydride modified cantharidin analogues, said process including the steps of:
- 10 dissolving a diene in a suitable solvent and adding to the resultant solution an ene.
11. A process for producing anhydride modified cantharidin analogue, said process including the steps of:
- dissolving a furan in a suitable solvent and adding to the resultant solution an
15 ene:
- incubating the solution at a temperature and for a time sufficient to form a precipitate; and
- collecting the precipitate and recrystallising the analogue.
12. A process for producing anhydride modified cantharidin analogue, said process
20 including the steps of:
- mixing thiophene and maleic anhydride at room temperature in a suitable solvent;
- compressing the mixture at a temperature and pressure sufficient to facilitate a reaction to take place: and


purifying the analogue.

13. A method of treating cancer which method comprises administering to a patient in need of such treatment, an effective amount of an inhibitor according to any one of claims 1 to 3 or a compound according to any one of claims 4 to 6, together with a
5 pharmaceutically acceptable carrier, diluent and/or excipient.
14. A method according to claim 13, wherein the cancer is inherently resistant to conventional chemotherapy.
15. A method according to claim 13 or claim 14, wherein the cancer is colon cancer or non small-cell lung cancer.
- 10 16. A method according to any one of claims 13 to 15, wherein the inhibitor or the compound is administered intravenously.
17. A method of sensitising cancer cells to at least one method of treating cancer, which method of sensitising comprises administering to a patient in need of such treatment, an effective amount of an inhibitor according to any one of claims 1 to 3 or a
15 compound according to any one of claims 4 to 6, together with a pharmaceutically acceptable carrier, diluent and/or excipient.
18. A method according to claim 17, wherein the at least one cancer treatment is selected from treatments involving irradiation and anti-cancer agents.
19. A method according to claim 17 or claim 18, wherein the cells have deficient
20 p53 activity.


20. A method of treating cancer which method comprises:
administering to a patient in need of such treatment, an effective amount of an
anhydride modified cantharidin analogue of any one of claims 1 to 3 or a compound
according to any one of claims 4 to 6 to sensitise cells of the patient to one or more
5 cancer treatments; and
utilising the one or more cancer treatments.
21. A method of screening compounds for use in sensitising cancer cells to at least
one method of treating cancer, and comprising:
screening for anti-cancer activity; and
10 screening for ability to abrogate either the G₁ or the G₂ checkpoint of the cancer
cell cycle.
22. A method according to claim 21 further comprising the step of screening for the
ability of the compounds of sensitise cancer cells to one or more cancer treatments.
23. A method according to claims 21 or 22 wherein the one or more cancer
15 treatments are selected from treatments involving cisplatin, irradiation, taxanes and
antimetabolites.
24. A method according to any one or claims 21 to 23 wherein the screening is
conducted on haematopoietic cells or solid tumour cells, having varying p53 activity.
25. A method according to claim 24, wherein the cells are selected from the group
20 consisting of L1210 (murine leukaemia, p53 wildtype), HL60 (human leukaemia, p53
nul), A2780 (human ovarian carcinoma, p53 wildtype), ADDP (cisplatin resistant A2780
cells, p53 mutant), SW480 (human colon carcinoma, p53 mutant), WiDr (human colon
carcinoma, p53 mutant), HT29 (human colon carcinoma, p53 mutant), HCT116 (human
colon carcinoma, p53 wildtype) and 143B (human osteosarcoma, p53 mutant).

26. A compound selected from a group comprising compounds (a) to (n) below:


(a)




(b)




(c)




(d)




(e)




(f)




(g)




(h)



(i)





(j)





(k)

(l)



(m)

(n)



27. Use of an inhibitor according to claim 1 or claim 2, or a compound according to any one of claims 3 to 5 for the manufacture of a medicament for the treatment of cancer.
28. Use according to claim 27, wherein the cancer is colon cancer or non small-cell lung cancer.
29. Use according to claim 27 or claim 28, wherein the medicament is administered intravenously.

1 / 27





FIGURE 1


FIGURE 2

Cantharidin and Cantharidin Analogues




Cantharidin

(2,3-dimethyl-7-oxobicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride)




MK-1

exo,exo 7-thia, 2-azabicyclohepta-5-ene-2,3-dicarboxylic acid anhydride




MK-2

bicyclo[2.2.1]heptane-5,6-ene-2,3-dicarboxylic acid anhydride




MK-3



MK-4


reduced lactol derivative of MK-2











MK-5

MK-7, MK-8, MK-9: isomers of MK-2


FIGURE 3






5/27

FIGURE 3 (cont'd)




6/27


FIGURE 3 (cont'd)



7/27

FIGURE 3 (cont'd)



8/27
FIGURE 3 (cont'd)

9/27

FIGURE 3 (cont'd)




FIGURE 3 (cont'd)




FIGURE 3 (cont'd)







FIGURE 3 (cont'd)







FIGURE 3 (cont'd)




FIGURE 3 (Cont'd)













FIGURE 4




Cell Cycle Analysis 12h following exposure to cantharidin, MK-2 or MK-4

FIGURE 5




Cell Cycle Analysis 18h after 6Gy of radiation and 12h after exposure to cantharidin, MK-2 or MK-4

FIGURE 6 (a)



Mhc99312.xls

FIGURE 6 (b)




Mhc99423.xls

19/27

FIGURE 6 (c)

Combination Index vs F_n Affected: HCT-116 cells,
simultaneous x72hr, CDDP & MK-4 various ratios, MTT




Mhc99942.xls

99510

FIGURE 7 (a)


Combination Index vs Fn Affected: HT29cells,
simultaneous x72hr, CDDP & MK-4 various ratios, MTT



Mh990416.xls

FIGURE 7 (b)

Combination Index vs F_n Affected: HT29cells,
simultaneous x72hr, CDDP & MK-4 various ratios, MTT



Mh990423.xls

22/27

FIGURE 8 (a)

Combination Index vs Fn Affected: HCT-116cells,
simultaneous x72hr, TXT & MK-4 various ratios, MTT





FIGURE 8 (b)


Combination Index vs F_n Affected: HCT-116cells,
simultaneous x72hr, TXT & MK-4 various ratios, MTT



Mhc99521.xls

FIGURE 8 (c)


**Combination Index vs Fn Affected: HCT-116cells,
simultaneous x72hr, TXT & MK-4 various ratios, MTT**



Mhc99528.xls

25/27


FIGURE 9 (a)



Mht99514.xls

FIGURE 9 (b)

Combination Index vs Fn Affected: HT29 cells,
simultaneous x72hr, TXT & MK-4 various ratios, MTT




Mht99521.xls

27/27

FIGURE 9 (c)

Combination Index vs F_n Affected: HT29 cells,
simultaneous x72hr, TXT & MK-4 various ratios, MTT



Mht99528.xls